If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Natural and Synthetic Biologically Active Dimeric Molecules: Anticancer Agents, Anti-HIV Agents, Steroid Derivatives and Opioid Antagonists

$63.10 plus tax (Refund Policy)

Buy Article:


Symmetry plays a crucial role in a variety of biological processes. For instance, many protein receptors, upon activation, dimerize to its active form and subsequently produce its biological action. Hence, there is a renewal of curiosity for the synthesis of dimeric molecules (or bivalent ligands) capable, not only to interact with specific biologic receptors, but also to induce greater biological responses than the corresponding monomeric counterpart. This is a vast and diverse theme of research. Hence, this review will discuss recent developments into this flourishing research field and will focus mainly into four specific topics namely dimeric 1) anticancer agents, 2) anti-HIV, 3) steroid derivatives and 4) opioid antagonists.

Keywords: anti-HIV agents; anticancer agents; dimeric molecules; drug design; opioid antagonists; steroid derivatives; symmetry

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986706775197908

Affiliations: Groupe de Recherche en Biopathologies Cellulaires et Moleculaires, Departement de Chimie- Biologie, Universite du Quebec a Trois-Rivieres, C.P. 500, Trois-Rivieres, Quebec, Canada, G9A 5H7.

Publication date: January 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more